Mar 12, 2025 5:08pm EDT SCYNEXIS Reports Full Year 2024 Financial ResultsĀ and Provides Corporate Update
Dec 18, 2024 8:00am EST SCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections